BOGGIANI, Daniela
 Distribuzione geografica
Continente #
NA - Nord America 260
EU - Europa 217
AS - Asia 62
Continente sconosciuto - Info sul continente non disponibili 1
Totale 540
Nazione #
US - Stati Uniti d'America 259
IE - Irlanda 94
SE - Svezia 62
CN - Cina 56
IT - Italia 27
DE - Germania 16
FI - Finlandia 6
RU - Federazione Russa 4
BE - Belgio 3
IN - India 3
GB - Regno Unito 2
TR - Turchia 2
A1 - Anonimo 1
CA - Canada 1
CZ - Repubblica Ceca 1
ES - Italia 1
NL - Olanda 1
SG - Singapore 1
Totale 540
Città #
Chandler 94
Dublin 94
Beijing 26
Ashburn 15
Shanghai 14
Bremen 12
New York 12
Princeton 12
Seattle 12
Ann Arbor 11
Dearborn 8
Des Moines 8
Wilmington 8
Helsinki 6
Ardea 4
Cascina 4
Boardman 3
Brussels 3
Parma 3
Bologna 2
Falls Church 2
Fremont 2
Los Angeles 2
Nanchang 2
Pavia 2
Rio Saliceto 2
Rome 2
Brooklyn 1
Edinburgh 1
Fairfield 1
Frankfurt am Main 1
Guangzhou 1
Hebei 1
Huizen 1
Izmir 1
Jiaxing 1
Kocaeli 1
Kunming 1
London 1
Madrid 1
Milan 1
Montreal 1
Moscow 1
Piacenza 1
Prague 1
Pune 1
Redwood City 1
Rockville 1
Shenyang 1
Shenzhen 1
Stockholm 1
Taglio Di Po 1
Taizhou 1
Tianjin 1
Woodbridge 1
Totale 393
Nome #
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 57
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 56
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 50
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 47
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 46
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 44
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 41
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 40
EGFR and EML4-ALK gene mutations in NSCLC: A case report of erlotinib-resistant patient with both concomitant mutations 36
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 35
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 32
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 25
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 24
Feasibility of Eribulin Mesylate in older patients with locally advanced or metastatic breast cancer: A post-hoc analysis of the ESEMPiO study 18
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 12
Totale 563
Categoria #
all - tutte 2.503
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.503


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20191 0 0 0 0 0 0 0 0 0 0 1 0
2019/202060 2 1 0 0 4 6 2 2 1 34 8 0
2020/202143 2 5 0 3 3 6 9 7 4 2 1 1
2021/202244 0 1 5 0 2 0 3 4 1 0 1 27
2022/2023315 25 34 19 22 34 33 2 23 112 1 8 2
2023/202499 2 14 1 2 3 22 10 22 4 18 1 0
Totale 563